PMID- 15818597
OWN - NLM
STAT- MEDLINE
DCOM- 20051003
LR  - 20220309
IS  - 0894-1491 (Print)
IS  - 0894-1491 (Linking)
VI  - 51
IP  - 4
DP  - 2005 Sep
TI  - Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
PG  - 279-85
AB  - Immunotherapy for malignant gliomas is being studied as a possible adjunctive 
      therapy for this highly fatal disease. Thus far, inadequate understanding of 
      brain tumor immunology has hindered the design of such therapies. For instance, 
      the role of microglia and macrophages, which comprise a significant proportion of 
      tumor-infiltrating inflammatory cells, in the regulation of the local anti-tumor 
      immune response is poorly understood. To study the response of microglia and 
      macrophages to known activators in brain tumors, we injected CpG 
      oligodeoxynucleotide (ODN), interferon-gamma (IFN-gamma), and IFN-gamma/LPS into 
      normal and intracranial RG2 glioma-bearing rodents. Microglia/macrophage 
      infiltration and their surface expression of MHC class II B7.1 and B7.2 was 
      examined by flow cytometry. Each agent evaluated yielded a distinct 
      microglia/macrophage response: CpG ODN was the most potent inducer of 
      microglia/macrophage infiltration and B7.1 expression, while IFN-gamma resulted 
      in the highest MHC-II expression in both normal and tumors. Regardless of the 
      agent injected, however, MHC-II induction was significantly muted in tumor 
      microglia/macrophage as compared with normal brain. These data suggest that 
      microglia/macrophage responsiveness to activators can vary in brain tumors when 
      compared with normal brain. Understanding the mechanism of these differences may 
      be critical in the development of novel immunotherapies for malignant glioma.
CI  - (c) 2005 Wiley-Liss, Inc.
FAU - Schartner, Jill M
AU  - Schartner JM
AD  - Department of Neurological Surgery, University of Wisconsin School of Medicine, 
      Madison, WI 53792-3232, USA.
FAU - Hagar, Aaron R
AU  - Hagar AR
FAU - Van Handel, Michelle
AU  - Van Handel M
FAU - Zhang, Leying
AU  - Zhang L
FAU - Nadkarni, Nivedita
AU  - Nadkarni N
FAU - Badie, Behnam
AU  - Badie B
LA  - eng
GR  - CA14520-29/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Glia
JT  - Glia
JID - 8806785
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (CPG-oligonucleotide)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adjuvants, Immunologic/pharmacology
MH  - Animals
MH  - Brain Neoplasms/*immunology/metabolism/therapy
MH  - Cell Line
MH  - Encephalitis/chemically induced/*immunology/metabolism
MH  - Glioma/*immunology/metabolism/therapy
MH  - Gliosis/chemically induced/*immunology/metabolism
MH  - Histocompatibility Antigens Class II/drug effects/*immunology/metabolism
MH  - Immunotherapy/methods
MH  - Inflammation Mediators/pharmacology/therapeutic use
MH  - Interferon-gamma/pharmacology
MH  - Lipopolysaccharides/pharmacology
MH  - Macrophages/drug effects/immunology/metabolism
MH  - Microglia/drug effects/*immunology/metabolism
MH  - Oligodeoxyribonucleotides/pharmacology
MH  - Rats
MH  - Rats, Inbred F344
MH  - Up-Regulation/drug effects/immunology
EDAT- 2005/04/09 09:00
MHDA- 2005/10/04 09:00
CRDT- 2005/04/09 09:00
PHST- 2005/04/09 09:00 [pubmed]
PHST- 2005/10/04 09:00 [medline]
PHST- 2005/04/09 09:00 [entrez]
AID - 10.1002/glia.20201 [doi]
PST - ppublish
SO  - Glia. 2005 Sep;51(4):279-85. doi: 10.1002/glia.20201.